Navigation Links
Codexis R&D Productivity Panels Also Used By Roche
Date:5/12/2009

REDWOOD CITY, Calif., May 12 /PRNewswire/ -- Codexis, Inc. today announced an agreement with Roche under which Roche will purchase Codex(TM) Biocatalyst Panels, a biocatalysis-based research and manufacturing productivity product.

The Codex(TM) Panels are used by pharmaceutical manufacturers to increase manufacturing productivity while reducing cost. They are based on Codexis proprietary custom biocatalysts, which can accelerate production of human therapeutics through early development of faster, lower cost, cleaner manufacturing processes. They have been used by more than 10 pharmaceutical companies worldwide.

"We are very pleased that Roche, a world leading company, will use Codexis biocatalysis technology to enhance pharmaceutical process manufacturing productivity," said Peter Seufer-Wasserthal, Ph.D., Senior Vice President, Codexis Pharmaceuticals. "Since their introduction in 2007, the Codex(TM) panels have been used to generate first kilogram quantities of a target material in weeks, instead of months. Some processes have already advanced to commercial scale. Shorter development time can contribute to lower drug development costs over many years - a priority in tight economic times."

Biocatalysts enable development of environmentally-friendly, low cost methods to produce chirally pure chemicals and have already replaced chemocatalysts in certain processes. Codexis offers panels covering major classes of enzymes that can produce a broad range of chemicals widely used by the pharmaceutical industry.

Sets of diagnostic enzyme panels are provided in a convenient 96-well format to efficiently determine if a biocatalytic solution is available for a challenging process step in the production of active pharmaceutical ingredients and intermediates needed to produce human therapeutics. Panel data is then used to rapidly develop product-specific, customized biocatalysts and biocatalytic processes for Codexis' pharmaceutical partners.

Codexis Inc. is a clean technology company. The company develops industrial biocatalysts, including enzymes and microbes. Codexis technology is used in the energy industry to enable next generation, non-food biofuels and by global pharmaceutical companies for cost-effective manufacturing of human therapeutics. Future commercial applications include carbon management, water treatment and chemical manufacturing. For more information, visit www.codexis.com.

Contact: Lyn Christenson, lyn.christenson@codexis.com, 650-421-8144 or Saskia Sidenfaden, ssidenfaden@mww.com, 212-827-3771


'/>"/>
SOURCE Codexis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Codexis Names Lori Giver VP Systems Biology
2. Codexis, Teva in Licensing Agreement Final
3. Codexis Names Vice President, Intellectual Property
4. Codexis, Arch Announce Expanded Collaboration
5. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
6. Codexis Names David Anton VP Bioindustrials R&D
7. Codexis Launches Codex(TM) MicroCyp Platform to Produce Drug Metabolites and Novel Lead Compounds
8. Rothwell, Wolf Elected to Codexis Board
9. Codexis Opens Singapore Laboratory
10. Bruce Pasternack Elected to Codexis Board
11. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)...  According to Kalorama Information, the dominant trends ... include significant efforts in automation as well as ... affordable sequencers, say the healthcare market research firm, ... sample prep materials.  The healthcare market research company,s ... Next Generation Sequencing (NGS) , highlights major trends ...
(Date:6/22/2016)... DIEGO , June 22, 2016   ViaCyte, ... first pluripotent stem cell-derived islet replacement therapy for the ... presentations at ISSCR 2016 Annual Meeting.  ISSCR 2016, the ... to 25th at Moscone West in San Francisco.  ... of the presentations are as follows:Event: , Focus Session: ...
(Date:6/22/2016)... 22, 2016  Mesa Biotech Inc., a privately-held, ... platform designed specifically for point-of-care (POC) infectious disease ... advisory board (SAB). Approved by the executive leadership ... chartered to advise on the development and commercialization ... by Dr. Steve Young , this world-class ...
(Date:6/21/2016)... , June 22, 2016 Frontier Biotechnologies Inc. ... its novel patch product AB001 met primary endpoint at ... relief against placebo. Conducted at nine clinical centers in ... enrolled 146 patients with chronic low back pain. AB001 ... week-1 (p=0.024), (2) greater reduction than placebo in the ...
Breaking Biology Technology:
(Date:6/16/2016)... FRANCISCO , June 16, 2016 ... size is expected to reach USD 1.83 ... by Grand View Research, Inc. Technological proliferation and ... banking applications are expected to drive the market ... ) , The development of advanced ...
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
(Date:5/24/2016)... care by providing unparalleled technology to leaders of the medical imaging industry.  As such, ... to the range of products distributed by Ampronix. Photo - http://photos.prnewswire.com/prnh/20160524/371420 ... ... ... With ...
Breaking Biology News(10 mins):